Goldman Sachs
SCPS

Goldman Sachs’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

Goldman Sachs’s Portfolio SCPS Stock Details SCPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-17,405
Closed -$7K – 6753
2022
Q2 		$7K Buy
+17,405
New +$8.36K ﹤0.01% 6316

Other funds holding SCPS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MRCM
M&R Capital Management Summit, New Jersey $454M AUM 40.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return

Goldman Sachs's SCPS Position: Q3 2022 in Review

Goldman Sachs sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q3 2022, closing a stake of 17,405 shares — an estimated $7K sold.

Goldman Sachs first reported a position in SCPS in Q2 2022 and held it in 1 quarter. The position peaked at $7K in Q2 2022. 15 funds tracked by Wall St. Rank hold SCPS as of Q3 2022.

  • Goldman Sachs reported no remaining Scopus BioPharma Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Goldman Sachs sold 17,405 Scopus BioPharma Inc. Common Stock shares in Q3 2022, an estimated $7K.
  • Goldman Sachs first reported a position in Scopus BioPharma Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Goldman Sachs's Scopus BioPharma Inc. Common Stock position peaked at $7K in Q2 2022.
  • 15 funds tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.